Evidence map›Paper›PMID 34645928›Full record

ArticleScientific reports2021

In vivo evaluation of GG2-GG1/A2 element activity in the insulin promoter region using the CRISPR-Cas9 system.

Hirofumi Noguchi, Chika Miyagi-Shiohira, Takao Kinjo, Issei Saitoh, Masami Watanabe

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hirofumi NoguchiDepartment of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, 903-0215, Japan. noguchih@med.u-ryukyu.ac.jp.
Chika Miyagi-ShiohiraDepartment of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, 903-0215, Japan.
Takao KinjoDepartment of Basic Laboratory Sciences, School of Health Sciences in Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, 903-0215, Japan.
Issei SaitohDepartment of Pediatric Dentistry, Asahi University School of Dentistry, Hozumi, Mizuho, 501-0296, Japan.
Masami WatanabeDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, 700-8558, Japan.
University of the Ryukyus · JPAsahi University · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The insulin promoter is regulated by ubiquitous as well as pancreatic β-cell-specific transcription factors. In the insulin promoter, GG2-GG1/A2-C1 (bases - 149 to - 116 in the human insulin promoter) play important roles in regulating β-cell-specific expression of the insulin gene. However, these events were identified through in vitro studies, and we are unaware of comparable in vivo studies. In this study, we evaluated the activity of GG2-GG1/A2 elements in the insulin promoter region in vivo. We generated homozygous mice with mutations in the GG2-GG1/A2 elements in each of the Ins1 and Ins2 promoters by CRISPR-Cas9 technology. The mice with homozygous mutations in the GG2-GG1/A2 elements in both Ins1 and Ins2 were diabetic. These data suggest that the GG2-GG1/A2 element in mice is important for Ins transcription in vivo.

Indexed as

Promoter Regions, GeneticAnimalsCRISPR-Cas SystemsFemaleGlucose Tolerance TestHomozygoteInsulinInsulin-Secreting CellsIslets of LangerhansMaleMiceMice, Inbred C57BLMutationPancreasTranscription FactorsTranscription, GeneticInsulinTranscription Factors

Identifiers

PMID34645928
PMCPMC8514523
OpenAlexW3206075016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.